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Abstract: Nutrition support practitioners are currently dealing with shortages of parenteral
nutrition micronutrients, including multivitamins (MVI), selenium and zinc. A recent
survey from the American Society of Enteral and Parenteral Nutrition (ASPEN) indicates
that this shortage is having a profound effect on clinical practice. A majority of
respondents reported taking some aggressive measures to ration existing supplies. Most
premature infants and many infants with congenital anomalies are dependent on parenteral
nutrition for the first weeks of life to meet nutritional needs. Because of fragile health and
poor reserves, they are uniquely susceptible to this problem. It should be understood that
shortages and rationing have been associated with adverse outcomes, such as lactic
acidosis and Wernicke encephalopathy from thiamine deficiency or pulmonary and skeletal
development concerns related to inadequate stores of Vitamin A and D. In this review, we
will discuss the current parenteral shortages and the possible impact on a population of
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very low birth weight infants. This review will also present a case study of a neonate who
was impacted by these current shortages.
Keywords: TPN; premature infant; nutrient deficiencies; neonate

1. Introduction
Product shortages in the healthcare system can have a significant impact on the care provided to
patients. In the case of premature or ill infants, high nutrient needs and a lack of nutrient stores make
the appropriate administration of nutrition essential. At birth, the clamping of the umbilical cord
immediately disrupts the delivery of nutrients from the placenta, which places these infants into a
situation that makes adequate provision of nutrients extremely important and challenging. Though the
preferred method of feeding, enteral feedings are often delayed in the premature infant due to the
fragility and medical complications associated with prematurity. Management of co-morbid
conditions, such as patent ductus arteriosis, chronic lung disease and feeding intolerance frequently
involve restriction of fluids and delays in enteral feeding advancement. As a result, these cases usually
remain dependent on parenteral nutrition (PN) for the first few weeks of life; however, those with
complications, such as necrotizing enterocolitis, may require sole PN for much longer time periods. In
the infant with congenital anomalies, such as gastroschisis, trachea-esophageal fistula or bowel
disease, feedings may not be feasible for weeks or even months. There is growing evidence that
inadequate nutrition in the first few weeks of life results in growth failure and poor long-term
neurodevelopmental outcomes [1,2]. Due to concern for current shortages of parenteral nutrition (PN)
micronutrient additives, the purpose of this paper is to review the potential effect of these shortages on
premature and newborn infants and to present a case study of nutrient deficiency resulting from
this shortage.
2. Current Shortages and TPN Management Strategies
According the American Society for Enteral and Parenteral nutrition (ASPEN), all PN products,
aside from dextrose and water, have been in short supply at some point since the spring of 2010
(see Table 1) [3]. At the time of this writing, a number of PN products continue to be unavailable or in
short supply. The current status of these and other drug products can be accessed at the Food and Drug
Administration web site [4].
Table 1. Parenteral Shortages 2010–2012.
Amino Acids
Calcium Gluconate
Cyanocobalamin
Magnesium Sulfate
Potassium Acetate
Sodium Acetate
Vitamin A

Ascorbic Acid
Chromium
Fat Emulsions
Multivitamins (MVI)
Potassium Phosphate
Sodium phosphate
Zinc

Calcium Chloride
Copper
L-cysteine
Phytonadione (vitamin K)
Selenium
Trace Elements

Nutrients 2012, 4

1979

ASPEN has provided timely and comprehensive advice to clinicians for dealing with PN product
shortages. Recommendations for conserving products during shortages of electrolytes, vitamins and
minerals are included in Table 2.
Table 2. ASPEN Recommendations for Conservation of PN Products.
1.
2.
3.
4.
5.
6.

Consider oral or enteral administration
Prioritize patients, saving supplies for those most vulnerable patients
Eliminate adding injectable electrolytes/minerals to enteral nutrition products
Minimize the use of additives to daily maintenance IV fluids
Reevaluate replacement algorithms or treatment protocols
Carefully evaluate alternative supplies of individual and multiple electrolyte products that are
available, including standardized, commercially available PN products

In a recent survey conducted by ASPEN, 25% of respondents stated their hospitals are in short
supply of pediatric multi-dose products, and 28% indicated they are in short supply of single-dose
products, such as selenium. When asked what actions were being employed in response to these
shortages, 70% reported giving multivitamins (MVI) only three times per week, 28% were giving half
the recommended dose daily, 27% were giving no MVI and 9% were giving adult MVI to pediatric
patients [3].
Product shortages are not new and have historically been documented to cause morbidity and
mortality. The omission of vitamins from PN has been associated with death as far back as 1989, when
three people at a large university medical center died from refractory lactic acidosis caused by
receiving thiamine-deficient PN [5]. In 1997, three additional patients receiving thiamine-free TPN
due to a national shortage developed lactic acidosis, and later, in 1998, a case report of Wernicke
encephalopathy and beriberi due to a multivitamin shortage was published [6]. Due to the historical
documentation of such adverse outcomes in adults, we sought documentation of the potentially adverse
effects in high-risk, premature infants.
3. Nutritional Needs of Preterm Infants and Potential Effect of Shortages of PN Components
Proteins and Amino Acids: Per kilogram, premature infants have among the highest protein needs of
any population during the lifecycle. Adequate protein provision of up to 4–4.5 g/kg/day is required for
very low birthweight infants to match intrauterine accretion rates and to promote appropriate
growth [7,8]. Adequate growth during Neonatal Intensive Care Unit (NICU) hospitalization is essential
to reduce the risk for negative outcomes associated with growth restriction, including chronic lung
disease, cerebral palsy, neurological impairment and rehospitalization after discharge [3,9]. The early
administration of parenteral protein helps to offset the nutritional deficits that begin with preterm birth
and continue throughout the infant’s hospitalization [10]. Early administration of PN that meets protein
goals has been associated with improvements in both short-term [11] and long-term growth [1]. In
contrast, infants not receiving early administration of amino acids have been found to have suboptimal
head growth at 18 months of age [1]. Restrictions in head circumference growth are especially
concerning, given the association between poor head growth and decreased neurodevelopmental
outcomes [12]. Likewise, goal provisions of both protein and energy during the first week of life may

Nutrients 2012, 4

1980

positively influence 18-month developmental outcomes [13]. Furthermore, shortages of individual
amino acids can have a profound effect on premature infant outcomes. For example, supplementation
of neonatal PN with cysteine has been associated with improved nitrogen balance, which may support
appropriate growth for both weight and head circumference [14,15]. The addition of cysteine may also
help to lower the pH of the PN mixture. This allows increased amounts of calcium and phosphorus to
be provided with a decreased risk for mineral precipitation, further promoting adequate bone
mineralization and growth [16]. Consequently, shortages of amino acid formulations impacting early
and adequate provision of protein in this population can have significant long-term ramifications.
Lipids: Fat provision is essential for life, but most specifically for premature infants to promote
normal growth and development. Fat is the most calorically-dense nutrient and aids in the development
of cells, the eye and the brain. Without lipid provision to PN-dependent infants, essential fatty acid
deficiency (EFAD) develops quickly as there are reports as early as the second day of life [17]. EFAD
may result in failure to thrive, dermatitis, thrombocytopenia, susceptibility to infection and poor would
healing [17]. Fat-free PN as the primary source of nutrition may further result in suboptimal calorie
provision and associated growth restriction. Increased total caloric intake in the first week of life has
been associated with improved Bailey MDI scores in a preterm infant population [13].
Minerals: In addition to macronutrient shortages, micronutrient shortages have the potential to
significantly impact the health of infants. One PN additive that is commonly used among the
premature infant population is calcium gluconate. Although higher in aluminum content than other
available PN calcium salts, calcium gluconate is often the additive of choice due to its favorable
solubility curves, allowing for higher calcium and phosphorus administration. Like protein, calcium
and phosphorus needs in premature infants remain high. Approximately 80% of total body calcium,
phosphorus and magnesium at birth are accrued within the last trimester of pregnancy. Consequently,
infants born prematurely have inadequately mineralized bones and require higher weight-based
provisions of calcium and phosphorus compared to infants born at term [8]. Adequate magnesium
provision is also necessary to promote bone growth, as hypomagnesaemia may hinder calcium
absorption. In addition, many common medications used for NICU infants can decrease calcium and
magnesium absorption, including diuretics, steroids and anti-convulsants [8,18]. It has been
well-documented that premature infants receiving inadequate amounts of calcium and phosphorus
from PN have higher incidences of osteopenia and elevated levels of serum alkaline phosphatase,
which may indicate poor bone mineralization and rapid bone turnover [19]. Clinical manifestations of
poorly mineralized bone will vary depending on the degree of bone mineralization. Bone fractures may
develop in these infants as a result and may negatively affect the stability of the chest wall, which can
lead to atelectasis or an increased risk of chronic lung disease [14].
Trace Elements: Only two trace elements are recommended on the initial day of PN; zinc and
selenium. Other trace elements are not thought to be needed until after two weeks of age [14]. Zinc is a
cofactor in more than 300 metabolic processes and supports protein and nucleic acid synthesis,
immune function, gene expression and growth. Two-thirds of the total body zinc is transferred from
mother to fetus during the last trimester of pregnancy and serum levels of zinc decline progressively in
infants on zinc-free PN [20]. As a result, ill neonates are at a high risk of developing zinc deficiency if
adequate supplementation cannot be provided. Additionally, most commercially-available trace
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element formulations contain insufficient zinc to meet the needs of the preterm infant. Therefore,
supplemental zinc must be added to PN, creating an additional mechanism for shortages.
Selenium is a component of glutathione peroxidase, a compound which protects against free radical
injury. Premature infants are often exposed to high levels of oxygen and resulting oxidative stress. It
has been speculated, though not proven, that selenium could be an important contributing factor in the
pathogenesis of disorders, such as bronchopulmonary dysplasia [21]. Most of the placental transfer of
selenium occurs after the 36th week of gestation [20]; hence, most premature infants will be born
selenium-depleted. Serum selenium concentrations have been shown to decrease quickly in infants
treated for respiratory distress syndrome who receive selenium-free or selenium-deficient PN [22]. A
2009 Cochrane review of selenium supplementation suggested that the currently recommended dose of
selenium (2 µg/kg/day) for preterm infants receiving parenteral nutrition is inadequate to maintain
selenium concentrations, so a dose of 3 µg/kg/day may be more appropriate to achieve concentrations
found in healthy breast-fed infants [23]. As current shortages make it difficult to provide even the
previously recommended amounts, implementing new evidence-based recommendations for increased
nutrient dosing becomes nearly impossible.
Inadequate provision of many other trace elements also poses nutritional risks for premature infants.
For example, both rapid growth and limited stores make premature infants at risk for copper
deficiency, which can result in osteoporosis, neutropenia or hypochromatic anemia [17]. Like zinc and
selenium, accretion of these nutrients occurs primarily during the last trimester of pregnancy, so
adequate provision is essential.
Vitamins: Premature infants require higher amounts of most vitamins when compared to term
infants, due to increased nutrient losses or increased requirements for growth. Recent studies have
documented nutrient deficiencies, specifically vitamin D deficiency, are highly prevalent in preterm
births [24–27]. Vitamin D supplementation during infancy is associated with increased bone mass in
childhood [28]. Consequently, deficiency and inadequate supplementation may result in rickets or
craniotabes [29]. Recent research has also expanded our understanding of vitamin D status during
infancy to include health benefits beyond bone status. Poor vitamin D status during early infancy is
now thought to be associated with other negative health outcomes, such as type 1 diabetes [30,31], and
pulmonary problems, such as respiratory tract infections or wheezing later in childhood [32–34]. The
current recommendation for parenteral vitamin D intake is 400 IU/day [8] which is the amount
included in 5 mL in most pediatric PN MVI formulations. Concerning, however, is that PN pediatric
MVI dosing is weight-based according to the manufacturer instructions; so many low birth weight
infants receive less than 5 mL (400 IU Vitamin D) daily. These dosing practices, combined with
product shortages, may make adequate administration of vitamin D challenging in infants dependent
on PN. Monitoring the vitamin D status of newborns is additionally challenging, as 25(OH)D levels
are not an accurate marker of vitamin D status in the newborn population. In 2006, Singh et al. showed
that a biologically inactive C-3 epimer of vitamin D is present in high levels in the bloodstream of
infants up to one year of age and may lead to an overestimation of vitamin D status in infants and
concerns regarding vitamin D overdosing in others [35].
Administration of vitamin E is recommended immediately after birth in premature infants, as some
older studies suggest a reduction in incidence and severity of intraventricular hemorrhage. A plasma
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target of >1 mg/dL by 24 h of life, and 2 mg/dL by three days of life has been recommended to reduce
IVH [14,36,37]. These levels should be attainable with the administration of current PN MVI
formulations, which would provide 2.8 mg/kg/day of vitamin E if given daily. However, limiting the
amount of MVI provided to premature infants, as many institutions are now being forced to do, could
negatively impact serum levels.
Vitamin A is necessary in premature infants for normal lung growth and for maintaining the
integrity of the respiratory epithelial track. Preterm infants are born with essentially no hepatic
reserves of Vitamin A, so levels of vitamin A at birth are reflectively low [38]. Therefore, Vitamin A
needs to be provided consistently from PN to promote adequate intake. However, a 2011 study
demonstrated that despite a policy to introduce intravenous-lipid supplemented PN by day of life two,
only 11% of infants consistently met the recommended daily intake of vitamin A during the first two
weeks of life [39]. Considering inadequate provision despite the best efforts, it remains concerning that
many PN-dependent infants are receiving reduced MVI dosing due to current shortages. The role of
vitamin A in preventing neonatal chronic lung disease has consistently been documented, including
evidence that intramuscular supplementation of vitamin A in extremely low birthweight infants
improves respiratory outcomes [38,40]. A meta-analysis of low birthweight infants demonstrated that
either enteral or parenteral supplementation with vitamin A reduced the risk of both death and oxygen
requirement at one month of age, and the risk of oxygen requirement at 36 weeks corrected gestational
age [38]. This practice may be limited, since intramuscular injections are considered painful; however,
current product shortages of the vitamin injections would inhibit this practice from being initiated in
NICUs targeting bronchopulmonary dysplasia (BPD). In addition to its role in lung integrity, vitamin
A appears critical in the development of ocular photoreceptors. During the third trimester of
pregnancy, the ocular content of rhodopsin (of which vitamin A is an essential component) increases
10-fold [39]. For the NICU hospitalized infant, an adequate substrate in the form of vitamin A needs to
be available to support this process in the extrauterine environment. Recommended PN administration
of vitamins and minerals discussed above are given in Table 3. Vitamin levels provided by current
MVI dosing guidelines are provided in Table 4.
Table 3. Recommended PN Administration of Select Nutrients *.
Calcium

Birth weight <1.5 kg
3 mEq/kg/day

Zinc

1000–3000 μg/kg/day

Selenium
Vitamin A
Vitamin D
Vitamin E

1.3–4.5 μg/kg/day
700–1500 IU/day
400 IU/day
6–12 IU/kg/day
* Adapted from [16].

Term Infants
2 mEq/kg/day
250 μg/day <3 months
100 µg/day >3 months
2.0 μg/day
2300 IU
400 IU/day
7 IU/day
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Table 4. Vitamin Levels Provided by Current Dosing of Pediatric MVI.

Vitamin C (mg)
Vitamin A (IU)
Vitamin D (IU)
Thiamine (B1) (mg)
Riboflavin (B2) (mg)
Pyridoxine (B6) (mg)
Niacin (mg)
Dexpanthenol (mg)
VitaminE (IU)
Vitamin K (mg)
Folic Acid (μg)
Biotin (μg)
B12 (μg)

Per 1.5 mL MVI
(<1000 g)
24
690
120
0.36
0.42
0.3
5.1
1.5
2.1
0.06
42
6
0.3

Per 3.25 mL MVI
(1001–2500 g)
5.2
1495
260
0.78
0.91
0.65
11.1
3.3
4.6
0.13
91
13
0.65

Per 5 mL MVI
(>2500 g)
80
2300
400
1.2
1.4
1
17
5
7
0.2
140
20
1

Epigenetic Ramifications of Early Neonatal Nutrition: In addition to the acute problems from
inadequate nutrient provision during the NICU stay, accumulating evidence implies that the early
prenatal period is critical for influencing disease risk for a range of disorders that may develop later in
life. There is considerable evidence suggesting that the risk of developing non-communicable diseases
can be altered by modifying influences of early-life environment, which includes nutritional factors.
This programming appears to be largely independent of genomic sequences and is likely to be
mediated by epigenetic mechanisms. Epigenetic programming during development is widely believed
to have a long-lasting effect on the health of a newborn [41]. Epigenetic changes are modification to
the DNA, which can be caused by various factors, including the environment, which do not change the
underlying sequence.
Studies have demonstrated that infants born prematurely have decreased insulin sensitivity when
compared with those born at term [42,43]. In one study of preterm vs. term infants and insulin
sensitivity, all of the infants born prematurely had inadequate protein intake in the first month of life,
which was proposed as a trigger to an epigenetic modification of genes involved in glucose
regulation [42]. Supplementation with vitamin D during infancy has been reported to confer protection
against beta-cell regulated autoimmune disorders [44,45]. A potentially very important activity of
vitamin D receptor agonists is their capacity to induce in vitro and in vivo tolerogenic dendrite cells,
which are able to enhance suppressor T-cells that, in turn, inhibit T-cell responses. Failure of tolerance
mechanisms may lead to auto-reactive T-cell activation and to induction of autoimmune diseases [46].
In a birth-cohort study published in 2001, Hypponen et al. found that vitamin D supplementation
during the first year of life is associated with a lower risk of type-1 diabetes [47]. This prospective
study followed 12,055 infants born in Finland and collected data in the first year of life regarding
vitamin D supplementation practices; later in life, data was collected on the diagnosis of type I
diabetes. At this time in Finland, the recommended level of Vitamin D supplementation for infants was
2000 IU daily, and infants in the study were classified as follows: receiving daily supplementation of
less than 2000 IU, within 2000 IU or over 2000 IU. Higher vitamin D supplementation in infancy was
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associated with a decreased frequency of Type 1 diabetes later in life when adjusted for neonatal,
anthropometric and social characteristics. Infants who regularly took the recommended dose of 2000
IU vitamin D per day had a relative risk (RR) of 0.22 (95% CI: 0.05–0.89) compared to those who
regularly received less than the recommended amount. Children suspected of having rickets during the
first year of life had a RR of 3.0 (95% CI: 1.0–9.0) compared with those without such a suspicion [31].
These results are consistent with the findings of the EURODIAB study in 1999, which was a large
multicenter and population-based case-control study on early risk factors of childhood onset Type I
diabetes. Vitamin D supplementation in early infancy to prevent rickets in seven different European
regions was also associated with a decreased risk for childhood-onset, insulin-dependent diabetes. The
favorable association with vitamin D supplementation persisted after adjustment for birth weight,
duration of breast feeding, maternal age and study center [30]. Additionally, vitamin D supplementation
in infancy has also been associated with a decreased risk of pre-eclampsia later in life [47].
Consideration of the potential for early nutrition interventions to have long-term health outcome
implications is crucial when designing nutrition support regimens for the premature infant population.
Potential Cost of Shortages: Poor outcomes attributable to PN shortages can quickly become costly
to both an infant’s health and associated healthcare costs. In 2007, the Journal of Pediatrics compiled
data regarding health care costs associated with initial hospitalization for premature infants. The data
clearly showed a monetary cost increase for all premature births compared to term births, but this cost
was four-to-seven-times higher for low birthweight infants with complications like chronic lung
disease or intraventricular hemorrhage. Additionally, 15% of all premature or low birthweight infants
were given a diagnosis of slow growth, malnutrition or small for gestational age. The cost for these
categorized infants was nearly $450 million [48]. Despite high health care costs, complications
associated with inadequate nutrition from PN shortages can have a much more devastating toll on
infant health. Complications, such as intraventricular hemorrhages or developmental delay, may
impact life-long ability and care requirements. Similarly, chronic diseases pose increased risks for
infections and infant mortality. Adequate provision of nutrients from PN is essential to help preserve
the health integrity of these infants, but unfortunately, PN shortages have the potential to do
the opposite.
Case Study: At our care facility, one infant on prolonged PN-developed selenium deficiency with
associated skin symptoms. This infant was born at an estimated gestational age of approximately
26 weeks with a birth weight of 790 g. The infant developed a bowel perforation within the first few
weeks of life and required surgery, with a resulting jejunostomy placement. The infant required both
sole and partial PN for most of his extensive hospital stay, and was approximately four months of age
when able to take full enteral feedings. Due to current shortages, no selenium was available to add to
the PN formulation. The infant developed dry, scaly skin and a selenium level was checked around
three months of life secondary to skin symptoms and recent PN additive shortages. The selenium level
was reported from the laboratory as 11 μg/L, which is well below the normal range for serum selenium
of 23–190 μg/L. Conditions, such as macrocytosis and fatal cardiomyopathy, have been reported when
selenium levels fall below 16 μg/L [23]. Once enteral feedings were established, 25 µg of oral
selenium was supplemented every other day, because no parenteral selenium was available. By
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discharge around five months of life, the infant was on calorically-dense full enteral feedings and his
skin symptoms had resolved, so at this point selenium supplementation was discontinued.
Potential Solutions: As is evident from Table 2, whenever possible during a shortage of PN
products, prioritization of resources is crucial in ensuring that the most vulnerable populations receive
critical products. Additional strategies to potentially maximize the nutrition status of premature infants
during PN product shortages should be explored. For instance, our care facility was forced to reduce
pediatric PN MVI to tri-weekly provision to conserve supplies. With the concern for inadequate
nutrient provision to our extremely and very low birthweight infants, we increased the weight-based
MVI dosing. For example, infants receiving 1.5 mL of PN MVI would receive 3.25 mL tri-weekly.
Though this is not a documented strategy, it does allow for a higher administration of nutrients while
conserving available local resources.
4. Conclusion
This review demonstrates the potential short-term and long term epigenetic impacts that current PN
shortages can have on premature and ill infants. Clinicians must, therefore, make decisions using
current evidence and clinical judgment to ensure avoidance of poor outcomes in situations where
adequate administration of all essential nutrients is not possible.
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